Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04494295 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation

Study acronym: MIRROR
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 19 to 20v17
  2. Study sites: 15 to 19v16
  3. Study sites: 12 to 15v15
  4. Site contacts updated at 8 of 12 sitesv14
  5. Site details revised at 2 of 12 sitesv13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites revised (12)v12
  2. Site details revised at 2 of 12 sitesv11
  3. Site details revised at 2 of 12 sitesv10
  4. Study sites: 10 to 12
    • Eligibility criteria revised
    v9
  5. Site details revised at 3 of 10 sitesv8
  6. Study sites revised (10)v7
  7. Study sites: 9 to 10v6
  8. Study sites: 3 to 9v5
  9. Study sites: 2 to 3v4
  10. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Oct 15, 2020 to Oct 23, 2020
    v3
  11. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This registry will study the use of the Aurora® Surgiscope to provide surgical access and visualization in minimally invasive removal of hematoma in the brain. Many methods of hematoma removal are available and will be based on surgeon preference. The impact of patient selection and time to surgery from last known well time will be explored.
Trial Details
NCT Number NCT04494295
Lead Sponsor Integra LifeSciences Corporation
Collaborators: Icahn School of Medicine at Mount Sinai, Oculus Imaging LLC
Conditions
(from sponsor)		 Supratentorial Hemorrhage
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov